Business-as-Usual will not Deliver the COVID-19 Vaccines We Need

Torreele, Els

doi:10.1057/s41301-020-00261-1

Cited by 8 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Las innovaciones en materia de salud que resulten de los esfuerzos colectivos, incluidas la financiación y las contribuciones intelectuales del sector público nacional y mundial, deben involucrar condicionamientos relativos al bien común, como el intercambio de conocimientos dentro de los países y entre ellos (93). Esto promovería un mayor rendimiento público y un acceso equitativo, y ayudaría a descentralizar la innovación y la capacidad de producción para mejorar la resiliencia mundial.…”

Section: Establecer Alianzas Simbióticas Entre Los Sectores Público Y...unclassified

Salud para todos: Transformar la economía para que proporcione lo que importa. Informe final del Consejo sobre los Aspectos Económicos de la Salud para Todos de la OMS

2024

View full text Add to dashboard Cite

El Consejo fue establecido a finales de 2020 por el Dr. Tedros Adhanom Ghebreyesus (Director General de la OMS) para proporcionar un nuevo pensamiento económico, reevaluando cómo se valoran, producen y distribuyen la salud y el bienestar en toda la economía. El Cons ejo, presidido por la profesora Mariana Mazzucato, está integrado por un grupo exclusivamente femenino de 10 distinguidas economistas y expertas en el área. El Consejo se ha centrado en reimaginar cómo poner la Salud para Todos en el centro de la toma de decisiones gubernamentales y la colaboración del sector privado a nivel regional, nacional e internacional. El Consejo –en este informe y en su trabajo anterior– ha recomendado enfoques políticos respaldados por esta nueva narrativa económica. Las decisiones que se tomen sobre cómo canalizar y dar forma a las inversiones públicas y privadas determinarán si el mundo continúa luchando con las consecuencias de los principales desafíos de salud o si logra crear una nueva economía política basada en la Salud para Todos.

show abstract

Section: Establecer Alianzas Simbióticas Entre Los Sectores Público Y...unclassified

Salud para todos: Transformar la economía para que proporcione lo que importa. Informe final del Consejo sobre los Aspectos Económicos de la Salud para Todos de la OMS

2024

View full text Add to dashboard Cite

show abstract

“…Many scholars have argued in favor of waiving IP rights, together with the expansion of production capacities in L&MICs (7,8,10,(12)(13)(14)(15)18,21,22,25,26,28,(30)(31)(32)(33)37,39,45,46,55). Others argue for tying access conditions to public funding for pharmaceutical research and development (R&D), in light of the large amount of public investments in the development of many COVID-19 vaccines during the pandemic (18,19,21,26,36,52,(56)(57)(58)(59)(60).…”

Section: Literature Review and Research Gapsmentioning

confidence: 99%

Which roads lead to access? A global landscape of six COVID-19 vaccine business models.

Ruiz,

Bezruki,

Shinabargar

et al. 2023

Preprint

View full text Add to dashboard Cite

3.1. Background Unequal and inequitable access to Covid-19 vaccines in low- and middle-income countries (L&MICs) was a major political, ethical and public health failure in the pandemic. However, vaccine developers’ practices were not monolithic, but rather, took diverse approaches to supplying different countries, with important implications for global access. 3.2. Results Using data on R&D investments, regulatory approvals, manufacturing and purchase agreements, and vaccine deliveries, we identified six distinct business models that apply across the 14 COVID-19 vaccines with more international presence from 2020–2022. “Western Early Arrivers” Pfizer/BioNTech and Moderna supplied the largest volumes quickly and prioritized high-income countries (HICs) from registration to vaccine delivery. “Western Latecomers” Janssen and Novavax supplied intermediate volumes later, also prioritizing HICs but with a greater proportion to L&MICs. “Major Chinese Developers” Sinopharm and Sinovac supplied intermediate volumes early, primarily to middle-income countries (MICs). “Russian Developer” Gamaleya completed development early but ultimately supplied small volumes, primarily to middle-income countries (MICs). “Cosmopolitan Developer” Oxford/AstraZeneca supplied large volumes early to HICs and MICs at the lowest prices. Finally, “Small MIC Developers” CanSino, Bharat Biotech, Medigen, Finlay Institute and the Center for Genetic Engineering and Biotechnology (CGEB), exported relatively small volumes to a few MICs. Low-income countries (LICs) were not targeted by any developer, and received far fewer doses, later, than any other income group. Almost all developers received public funding and other forms of support, but we found little evidence that such support was leveraged to expand global access. 3.3. Conclusions Each of the six business models has different implications for which countries get access to which vaccines, how quickly, and at which prices. Each offers different strengths and weaknesses for achieving equitable access. Our findings also suggest that Western firms had the greatest capacity to develop and deliver vaccines quickly during the pandemic, but such capacity is rapidly becoming more globally distributed with MICs playing a significant role, especially in supplying other MICs. Given the critical role of public support in enabling pandemic vaccine development and supply, governments have both the capacity and responsibility to craft international rules that will make responses to future pandemics more equitable and effective.

show abstract

“…Ademais, a transparência deve garantir também o detalhamento das contribuições dos investidores e seus riscos 40 .…”

Section: Essas Iniciativas De Governança Global Da Saúde Estão Servin...unclassified

Assistência Farmacêutica e governança global da saúde em tempos de Covid-19

Ribeiro

Ricardi²,

Pontes

et al. 2022

Saúde debate

View full text Add to dashboard Cite

RESUMO Este ensaio aborda como e em que níveis a Assistência Farmacêutica é atravessada pela dinâmica da governança global da saúde, e como se relaciona com aspectos geopolíticos e socioeconômicos. Tenta-se ir além do acesso a medicamentos e produtos para saúde, abordando também o uso racional de medicamentos, seu impacto na resistência aos antimicrobianos e na saúde dos povos. Além disso, discute como a Assistência Farmacêutica pode ser vista nesse contexto.

show abstract

Business-as-Usual will not Deliver the COVID-19 Vaccines We Need

Cited by 8 publications

References 12 publications

Salud para todos: Transformar la economía para que proporcione lo que importa. Informe final del Consejo sobre los Aspectos Económicos de la Salud para Todos de la OMS

Salud para todos: Transformar la economía para que proporcione lo que importa. Informe final del Consejo sobre los Aspectos Económicos de la Salud para Todos de la OMS

Which roads lead to access? A global landscape of six COVID-19 vaccine business models.

Assistência Farmacêutica e governança global da saúde em tempos de Covid-19

Contact Info

Product

Resources

About